Let's visit a bit on how Solazyme has been doing since it went public on May 26. I received this interesting analysis from the Buckingham Research Group on their June 7 coverage of Solazyme but unfortunately, I will not be able to share the report completely so I'll just post some of the more interesting analysis from this equity research.
Solazyme's initial IPO price was $15-17 when filed and has subsequently raised to $20/share, which then rose 20% post-offering to between $24/share. The offering size was also increased 10% from 10m shares to 11m. The company has a market cap of $1.1bn eventhough it has minimal product sales yet.